Chemotherapy with irinothecan, 5-fluorouracil and folinic acid in the first-line management of advanced colorectal carcinoma: Retrospective study [5]

Journal of Chemotherapy

Volumn 15, Issue 3, 2003, Pages 304-305

  Man, Sofia ^a,b   Lavrenkov, K ^a,b   Gluzman, A ^a,b   Geffen, D B ^a,b   Cohen, Y ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DIARRHEA; DISEASE COURSE; DRUG INFUSION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LETTER; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED STATES;

EID: 0038684055     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.3.304     Document Type: Letter

References (10)

1. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1996; 29A: 2077-92.
2. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
3. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinothecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15: 251-60.
4. Lavrenkov K, Man S, Mermershtain W, Cohen Y. Retrospective comparison of single agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer. J Chemother 2002; 14: 84-7.
5. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluouracil compared with fluouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-7.
6. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 543: 905-12.
7. Sargent D, Niedzwiecki D, O'Connell M, et al. Recommendation for caution with irinothecan, fluouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345: 144-5.
8. Rothenberg M, Meropol, Poplin E, et al. Mortality associated with irinothecan plus bolus fluouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-7.
9. Elfring G, Emanuel D, Rostagi R, et al. Patterns of use and mortality in the community oncology practice setting among patients receiving first-line weekly bolus irinothecan/5-fluouracil/leucovorin (IFL) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 21: 133a, (abstr 530).
10. Van Cutsem E, Douillard JY, Kohne C. Toxicity of irinothecan in patients with colorectal cancer. N Engl J Med 2001; 345: 1351-2.